GlassScriptPhysician profile
Alan M Schneider
NPI 1750331617
$5,540.56
in general payments reported to CMS, 2019-2025
31 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $749 · 2021: $932 · 2022: $707 · 2023: $748 · 2024: $891 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,005.48 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $991.70 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $589.70 | 2019-2025 | |
| Pfizer INC. | $316.73 | 2019-2025 | |
| Abbott Laboratories | $311.72 | 2019-2023 | Cardiomems |
| Irhythm Technologies, INC. | $304.38 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $268.49 | 2019-2025 | Watchman Flx, Emblem Mri S-Icd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $161.82 | 2022-2024 | Verquvo, Bridion |
| Sanofi-Aventis U.S. LLC | $144.79 | 2019-2023 | |
| Amarin Pharma, INC. | $139.24 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $120.55 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $118.89 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $102.72 | 2020-2024 | Wainua |
| Novo Nordisk INC | $97.04 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $95.02 | 2019-2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.97 | 2019-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $88.07 | 2021 | |
| Astellas Pharma US INC | $47.31 | 2019 | |
| Philips North America LLC | $43.36 | 2023-2025 | Neoview |
| Lemaitre Vascular, INC. | $42.83 | 2022 | |
| Lantheus Medical Imaging, INC. | $30.76 | 2022 | |
| Vital Connect, INC | $26.56 | 2025 | Vitalpatch Rtm |
| Lundbeck LLC | $22.53 | 2019 | |
| Genzyme Corporation | $20.06 | 2024 | |
| Z-Medica, LLC | $20.04 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.48 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $16.46 | 2023 | |
| Medtronic Vascular, INC. | $15.40 | 2019 | |
| Gilead Sciences, INC. | $12.24 | 2019 | |
| Esperion Therapeutics, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.